Press Releases


August 15, 2016: The Fox Chase Chemical Diversity Center Annouces it Has Been Awarded a Phase II STTR Grant from the National Institute of General Medical Science, with Prof. Thomas Smithgall, University of Pittsburgh as PI, Entitled "Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV AIDS"

July 5, 2016: The Fox Chase Chemical Diversity Center Announces that the FDA has Completed its Review of FC-4157 (also known as BHV-4157) Investigational New Drug Application (IND) Filed on May 31, 2016 by Biohaven Pharmaceutical Holding Company Ltd

February 10, 2016: The Fox Chase Chemical Diversity Center Announces it Has Been Selected to Participate in the Spring, 2016 I-Corps Program of the National Institutes of Health

October 21, 2015: The Fox Chase Chemical Diversity Center Announces it has Registered it's 5,000th FCCDC New Chemical Entity Since 2008

May 20, 2015: The Fox Chase Chemical Diversity Center Announces it is Working Together With the Wistar Institute to Discover Inhibitors of Epstein Barr Nuclear Antigen EBNA1 for the Treatment of Epstein Barr Virus-Mediated Cancers

March 26, 2015: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I SBIR Grant Entitled “Pregnane X Receptor (PXR) Antagonists for Non-Alcoholic Fatty Liver Disease”

December 29, 2014: The Fox Chase Chemical Diversity Center Announces it Has Received a $100,000 Keystone Innovation Zone Tax Credit from the Department of Community & Economic Development of the Commonwealth of Pennsylvania

September 8, 2014: The Fox Chase Chemical Diversity Center Will Be Presenting Riluzole Prodrugs to Treat ALS and Melanoma, Funded by a Phase II SBIR Grant, at the NCI SBIR Investor Forum on Nov. 13 in Santa Clara, CA

June 16, 2014: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded A Phase II SBIR Grant With the Title “A Novel Therapeutic for Invasive Candidiasis”

December 31, 2013: The Fox Chase Chemical Diversity Center Announces it HasSubmitted it's 3,000th Small Molecule Test Compound

August 23, 2013: The Fox Chase Chemical Diversity Center Announces that it Has Been Awarded a Phase I STTR Grant Together With Prof. Harvey Rubin of the University of Pennsylvania, “New Therapeutics for the Treatment of Acinetobactor baumannii Infections,” Totaling $300,000

More

Press Releases


August 15, 2016: The Fox Chase Chemical Diversity Center Annouces it Has Been Awarded a Phase II STTR Grant from the National Heart, Lung, and Blood Institute, with Bruce Sachais, MD, New York Blood Center as PI, Entitled "Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT"

March 31, 2016: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Direct-to-Phase II SBIR Grant from the National Institutes of Health Entitled "Development of Topical Antiviral Agents for Treating Molluscum Contagiosum"

October 30, 2015: The Fox Chase Chemical Diversity Center is Mentioned in a Press Release by the University of Pennsylvania

October 6, 2015: The Fox Chase Chemical Diversity Center Announces a Research Collaboration with Portage Biotech Inc. and Biohaven

May 11, 2015: The Fox Chase Chemical Diversity Center Announces that is Has Established a Strategic Partnership With the Prestigious Wistar Institute

February 2, 2015: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I SBIR Grant Entitled “Development of Drugs that Target the M2 Proton Channel from Influenza Virus”

January 23, 2015: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Entitled “Development of Small Molecule Therapeutics Against RNA Viruses”

December 24, 2014: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Direct to Phase II SBIR Entitled “Development of Small Molecule Therapeutics Against Smallpox and Other Poxviruses”

September 3, 2014: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Entitled “Small Molecule Inhibitors of HIV1 Nef Virulence Factor for Treatment of HIV/AIDS”

May 17, 2014: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase I STTR Grant From the National Heart, Lung, and Blood Institute Entitled “Small Molecule Antagonists of PF4 for the Treatment and Prevention of HIT”

August 23, 2013: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Phase II SBIR Grant, "Development of Small Antimicrobial Peptide Mimics,” Totaling $2,000,000

July 22, 2013: The Fox Chase Chemical Diversity Center Announces it Has Been Awarded a Small Business Phase I STTR Grant Entitled DC-SIGN Inhibitors for the Treatment of HIV Infection for $300,000

More